LUD 00-009: Phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer

NY-ESO-1 is a cancer-testis antigen and an attractive target for immunotherapy in patients with different malignancies. Here we report the results of a phase I clinical study of intensive course NY-ESO-1 peptide vaccination, evaluating the safety, immunogenicity and clinical response in HLA-A2 posit...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Bender, Armin, Karbach, Julia, Neumann, Antje, Jäger, Dirk, Al-Batran, Salah E., Atmaca, Akin, Weidmann, Eckhart, Biskamp, Melina, Gnjatic, Sacha, Pan, Linda, Hoffman, Eric, Old, Lloyd J., Knuth, Alexander, Jäger, Elke
Formato: Artigo
Idioma:Inglês
Publicado em: Academy of Cancer Immunology 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2935748/
https://ncbi.nlm.nih.gov/pubmed/17944437
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados